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Visfatin (also known as pre-B cell colony-enhancing factor)
is a newly discovered adipocytokine that is preferentially
produced by visceral fat and regulated by cytokines
promoting insulin resistance. Here we determined its renal
synthesis and physiology in a genetic model of type 2
diabetes in rats. These rats had higher levels of visfatin
synthesis in both glomeruli and tubulointerstitium compared
to control rats. Plasma visfatin levels were significantly
increased in the early stages of diabetic nephropathy and
positively correlated with body weight, fasting plasma
glucose, and microalbuminuria. Interestingly, visfatin
synthesis was found to occur in podocytes and proximal
tubular cells, as well as in adipocytes in vitro. Further, in both
renal cells, visfatin synthesis was significantly increased by
high glucose in the media but not by angiotensin II.
Additionally, visfatin treatment induced rapid uptake of
glucose and was associated with increased translocation of
GLUT-1 to the cellular membrane of both renal cell types.
Furthermore, visfatin induced tyrosine phosphorylation of
the insulin receptor, activated downstream insulin signaling
pathways such as Erk-1, Akt, and p38 MAPK, and markedly
increased the levels of TGFb1, PAI-1, type I collagen, and
MCP-1 in both renal cells. Thus, our results suggest that
visfatin is produced by renal cells and has an important
paracrine role in the pathogenesis of diabetic nephropathy.
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Chronic kidney diseases (CKDs) are increasing to epidemic
levels in the elderly and have been shown to be powerful
cardiovascular risk factors.1,2 Although a link between CKD
and cardiovascular disease has been noted in with diabetes or
non-diabetes patients,3 the highest incidence of cardiovas-
cular disease continues to be present in patients with both
diabetes and CKD.4 With respect to cardiovascular disease,
the identity of numerous adipocytokines has emerged in
obesity and metabolic syndrome research.5,6 Indeed, there
has been an evolving and intensive research effort on
adipocytokines since the discovery of leptin in 1994.7
Visfatin is a newly discovered adipocytokine that appears
to be preferentially produced by visceral fat.8 Visfatin is
identical to pre-B-cell colony-enhancing factor expressed in
lymphocytes.9 Expression of the pre-B-cell colony-enhancing
factor is regulated by cytokines that promote insulin
resistance such as lipopolysaccharide, interleukin-1, inter-
leukin-6, and tumor necrosis factor-a.10–12 A recent study
contradicts several previously published reports on visfatin.
This study failed to confirm original results from human
diabetic patients.13 Several subsequent reports have provided
evidence that visfatin is not an actual adipocytokine, but
rather a novel marker of inflammation. Visfatin expression
is increased in foam cell macrophages that have a role in
plaque destabilization within unstable atheroscletic regions.14
Plasma visfatin concentrations are related to endothelial
dysfunction in type-2 diabetic patients and patients with
CKD.15,16 In addition, visfatin expression is detected in
synovial fibroblasts in patients with rheumatoid arthritis, and
visfatin itself activates nuclear factor-kB and various related
pro-inflammatory cytokines in cultured synovial fibro-
blasts.17 Collectively, these results suggest a new physiological
role of visfatin in organ injury.
We have previously observed that visfatin synthesis is
increased by high glucose stimulus in mesangial cells, and
also that visfatin may contribute to increased glucose influx
in mesangial cells, thereby accelerating diabetic nephropathy
through aggravation of metabolic alterations.18 In this
study, we investigated whether visfatin synthesis is increased
in the diabetic kidney in type-2 diabetic rats, and evaluated
their association with several biochemical parameters.
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Additionally, to define the molecular mechanism of visfatin,
we evaluated the effect of high glucose on visfatin synthesis
and the effect of visfatin on glucose metabolism in both
podocytes and proximal tubular cells (PTCs). Finally, we
evaluated the direct effect of visfatin on the synthesis of
pro-inflammatory and pro-fibrotic cytokines synthesis in
cultured podocytes and PTCs.
RESULTS
Biochemical parameters in experimental animals
Table 1 shows the various biochemical results obtained for
each experimental group of animals. Fasting plasma glucose
levels were significantly higher in Otsuka Long-Evans
Tokushima Fatty (OLETF) rats (143.6±17 mg/dl) than
Long-Evans-Tokushima-Fatty (LETO) rats (108.0±10 mg/dl;
P¼ 0.026). Kidney/body weight was also significantly higher
in OLETF rats as compared with in LETO rats. There were no
significant differences in serum creatinine concentrations and
urine volume between the two groups. Systolic blood
pressure, measured at the end of the study period, was
greater in OLETF rats than in LETO rats. Urinary albumin
excretion in OLETF rats was significantly higher than in the
LETO rats at 20 weeks of age, and this difference was further
increased at the end of the study period. OLETF rats
exhibited marked glucose intolerance compared with LETO,
which was confirmed by an intraperitoneal glucose tolerance
test (GTT). In accordance with glucose intolerance, OLETF
rats showed significantly higher levels of plasma cholesterol
and triglyceride levels (cholesterol, LETO: 103±5.4, OLETF:
141±32, P¼ 0.027; triglyceride, LETO: 43±9, OLETF:
184±24, P¼ 0.003). Although plasma adiponectin levels
were not significantly different between the two groups,
plasma insulin levels were significantly higher in OLETF rats
than in LETO rats (LETO: 1.02±0.14, OLETF: 2.54±0.25,
P¼ 0.005). In addition, homeostasis model assessment
(HOMA) insulin resistance indexes (HOMA-IRs) also
showed significantly higher levels in OLETF rats as compared
with that in LETO rats (LETO: 0.43±0.11, OLETF:
0.63±0.06, P¼ 0.047). To examine the role of visfatin in
diabetic nephropathy, we measured the plasma concentra-
tions of visfatin at different time points in the experimental
rats. Visfatin levels were significantly elevated in OLETF rats
as compared with LETO rats at 20 weeks, which was during
the early stages of diabetic nephropathy, and this trend
continued until the end of the study period (Table 1).
Interestingly, plasma visfatin levels were positively correlated
with body weight, microalbuminuria, fasting plasma glucose
levels, and HOMA-IRs (Table 2).
Histopathological changes in experimental animals
Figure 1 shows representative renal pathology changes in the
experimental groups at the end of the study period.
According to a semi-quantitative scoring system, OLETF rats
showed more severe glomerulosclerosis than LETO rats
(Figure 1a and b); however, there were no remarkable
findings of tubulo-interstitial fibrosis even in OLETF rats,
which indicates that the differences were not significant. We
Table 1 | Biochemical parameters in experimental animals
LETO (20 weeks) OLETF (20 weeks) LETO (50 weeks) OLETF (50 weeks) P-value
Body weight (g) 316.6±32.5 472.3±31.2* 492.1±47.2 619.3±32.2* 0.025
Kidney/BW  103 NA NA 0.29±0.04 0.32±0.10* 0.036
FPG (mg/dl) 112±12.1 131.4±15.2* 108.0±10.0 143.6±17.0* 0.026
P-Cr (mg/dl) 0.54±0.12 0.55±0.25 0.67±0.05 0.58±0.13
UV (ml/day) 12.5±10.5 16.1±14.3 18.6±11.3 14.1±1.73
UAE (mg/mgCr/day) 42.36±11.52 84.3±11.5* 34.72±1.44 159.7±51.14# o0.001
SBP (mmHg) NA NA 128.5±20.6 147.2±18.1** 0.008
P-visfatin (pg/ml) 62.4±13.7 103.4±21.6* 68.3±46 108.5±19.4* 0.035
Cholesterol (mg/dl) NA NA 103.0±5.4 141.0±32.0* 0.027
Triglyceride (mg/dl) NA NA 43.0±9.01 184.0±24.0** 0.003
P-insulin (ng/ml) NA NA 1.02±0.14 2.54±0.25** 0.005
HOMA-IR NA NA 0.43±0.11 0.63±0.06* 0.047
GTT (basal) (mg/dl) NA NA 113.4±12.5 131.2±17.6
GTT (30min) (mg/dl) NA NA 201.5±22.4 465.2±37.0# o0.001
GTT (60min) (mg/dl) NA NA 188.3±27.6 410.0±41.2# o0.001
GTT (90min) (mg/dl) NA NA 151.5±19.6 355.7±16.6# o0.001
GTT (120min) (mg/dl) NA NA 116.9±10.7 298.6±15.2** 0.009
Abbreviations: BW, body weight; FPG, fasting plasma glucose; GTT, glucose tolerance test; HOMA-IR, the homeostasis model assessment index; NA, not available; P-Cr, plasma
creatinine concentration; P-visfatin, plasma visfatin concentration; SBP, systolic blood pressure; UAE, urinary albumin excretion; UV, urine volume.
The values are expressed as the mean±s.e.m. Statistical analyses were performed between LETO and OLETF groups at the same time periods. *Po0.05, LETO versus OLETF;
**Po0.01, LETO versus OLETF; #Po0.001, LETO versus OLETF (number of replicates for measurement; duplicates for P-Cr, UAE, P-visfatin, and lipid profile; n=10 for SBP
measurement).
Table 2 | Correlation analysis between plasma visfatin levels
and biochemical parameters in experimental animals
Parameters r-value P-value
Body weight 0.424 0.027
Microalbuminuria 0.317 0.031
Plasma creatinine 0.239 0.573
Systolic blood pressure 0.213 0.423
Fasting plasma glucose 0.551 0.021
Plasma insulin 0.243 0.231
Plasma adiponectin 0.263 0.371
HOMA-IR 0.351 0.044
Abbreviation: HOMA-IR, the homeostasis model assessment index.
Correlation analysis was performed using Spearman rank correlations.
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performed visfatin immunostaining and found that OLETF
rats exhibited markedly increased immunoreactivity in
both glomeruli and tubulo-interstitium when compared
with LETO rats. In addition, visfatin immunoreactivity
was primarily increased in the mesangium, podocytes,
and proximal tubular epithelium (Figure 1c and d,
Supplementary Figure S1).
Effect of high glucose and angiotensin II on visfatin
production in cultured podocytes and PTCs
To confirm the synthesis of visfatin in podocytes and murine
cortical tubule (MCT) cells, reverse transcription–PCR was
performed. We used 3T3-L1 adipocytes as positive controls
due to their high expression of visfatin. As shown in Figure 2a,
visfatin was also expressed in podocytes and MCT cells as
well as adipocytes. The effect of high glucose and angio-
tensin II on visfatin synthesis was subsequently examined.
Visfatin gene expression and protein synthesis were increased
significantly after high glucose stimulation in both podocyes
and MCT cells; however, angiotensin II stimulation did not
induce any changes in visfatin production (Figure 2b–f,
Supplementary Figure S2).
Effect of visfatin on 2-DOG uptake in podocytes and PTCs
To examine the biological effect of visfatin, we investigated
2-deoxyglucose uptake after visfatin stimulation in renal cells
using a 2-deoxy-D-glucose (2-DOG) uptake assay. First, a
time course of 2-DOG uptake after treatment with 100 ng/ml
of visfatin was performed. As shown in Figure 3, visfatin
treatment induced rapid uptake of 2-DOG in both podocytes
and MCT cells, with maximal stimulation at 20 min followed
by rapid decrease to control levels at 30 min. As expected,
insulin treatment induced rapid uptake of 2-DOG in renal
cells that peaked at 20 min. Cytochalasin-B, an endocytosis
inhibitor including glucose transporter, completely abolished
visfatin-stimulated glucose uptake to basal levels, showing
that visfatin-induced glucose uptake was mediated by glucose
transporters (Figure 3a and b). Furthermore, stimulation
of 2-DOG uptake by visfatin in MCT cells increased in a
dose-dependent manner beginning with a concentration of
10 ng/ml and reaching maximal stimulation at 100 ng/ml.
Conversely, there was no dose-dependent effect of visfatin-
induced glucose uptake in podocytes (Figure 3c and d).
Effect of visfatin on GLUT-1 synthesis and translocation
in podocytes and PTCs
Next, we investigated the ability of a glucose transporter to
mediate visfatin-induced glucose transport. Among the facil-
itative glucose transporters, glucose transporter-1 (GLUT-1)
has been shown to be the major glucose transporter in renal
cells, and thus the possibility that visfatin stimulation increases
the expression of GLUT-1 was examined. As shown in Figure 4,
visfatin treatment induced a significant increase in the mRNA
expression of GLUT-1 in both podocytes and MCT cells
(Figure 4a and b). To further confirm the translocation of
GLUT-1 to the cellular membrane, western blotting using the
membrane fraction of the cells was performed (Supplementary
Figure S3). As shown in Figure 4, GLUT-1 expression was
increased in the plasma membrane of cells after visfatin
stimulation. As positive control, GLUT-1 translocation into the
cell membrane induced by insulin stimulation was also
observed (Figure 4c and d).
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Figure 1 |Representative renal histology and immunohistochemistry for visfatin in experimental animals. (a) Periodic acid–Schiff
staining. (b) Glomerulosclerosis index. (c) Immunostaining for visfatin. (d) Immunostaining score for visfatin. Data are shown as the
mean±s.e.m. Original magnification  200. More than 50 and 60 glomeruli, and 10 randomly selected tubulointerstitial fields were
evaluated; **P¼ 0.007, LETO versus OLETF; ***Po0.001, LETO versus OLETF.
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Effect of visfatin on insulin signal transduction
We next examined whether visfatin-induced glucose uptake
occurs through insulin signaling pathway. First we observed
the effect of visfatin on the tyrosine phosphorylation of the
insulin receptor (IR). As shown in Figure 5, visfatin
stimulation induced tyrosine phosphorylation of IR and IR
substrate-1 (IRS-1), and binding of p85 to IRS-1 molecule in
both podocytes and MCT cells.
Effect of visfatin on Akt, Erk-1/2, p38 MAPK activation, and
pro-fibrotic molecule synthesis
As visfatin was found to increase glucose transport and
induce the tyrosine phosphorylation of the IR, we next
examined the effect of visfatin on Akt, extracellular signal-
regulated kinase-1 (Erk-1)/2, and p38 mitogen-activated
protein kinase (MAPK) activation, all of which are important
downstream components of the insulin signaling pathway. As
shown in Figure 6, activation of Akt and Erk-1/2, as assessed
by measuring the levels of phospho-specific Akt and Erk-1/2,
was found to rapidly increase in response to visfatin after
1 min, and then gradually decreased. Likewise, activation of
p38 MAPK was found to increase after 5 min, with maximal
activity occurring at 30 min followed by gradual decrease,
although to levels that remained higher than that in the
controls. By contrast, total Akt, Erk-1/2, and p38 MAPK
protein levels did not differ among the various treatment
groups.
Because visfatin increased glucose uptake and activated
the downstream components of the insulin signaling
pathway, we examined the effect of augmented glucose influx
induced by visfatin on changes in the synthesis of pro-
inflammatory and pro-fibrotic molecules such as transform-
ing growth factor-b1 (TGFb1), plasminogen activator
inhbitor-1 (PAI-1), monocyte chemoattractant peptide-1
(MCP-1), and collagen. As shown in Figure 6, visfatin
stimulation significantly increased the gene expression of
TGFb1, PAI-1, MCP-1, and type-I collagen in both podocytes
and MCT cells. Prior treatment with cytochalasin-B com-
pletely abolished visfatin-induced TGFb1, PAI-1, MCP-1, and
type-I collagen gene expression, which implied that the
overexpression of these targets induced by visfatin occurred
through an augmented glucose influx into cells. To further
confirm the effect of visfatin on MCP-1, PAI-1, and collagen
protein synthesis, ELISA and western blot analysis were
performed. As shown in Figure 7, MCP-1, PAI-1, and
collagen protein secretion was markedly increased by visfatin
treatment, which was completely abolished by treatment with
cytochalasin-B. As visfatin induced activation of MAPK, we
further examined whether pharmacological inhibitors of
MAPK inhibit visfatin-induced glucose uptake. As shown in
Figure 8, blockade of the MAPK pathway did not inhibit
visfatin-induced glucose uptake in both cells.
DISCUSSION
In this study, we found that visfatin was synthesized in both
renal cells and adipocytes, and that plasma visfatin
concentrations were significantly increased during the early
stages of diabetic nephropathy in type-2 diabetic rats.
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Figure 2 | Synthesis of visfatin and the effect of high glucose and angiotensin II on visfatin production in experimental cells. (a) PCR
results for visfatin in cultured cells. A representative reverse transcription-PCR showing a 143-bp product. As positive control, 3T3-L1
adipocytes were used. (b) Effect of high glucose and angiotensin II on visfatin mRNA expression in cultured cells. Effect of high glucose
and angiotensin II on visfatin protein secretion in cultured podocytes (c) and MCT cells (d). A representative western blot for visfatin in
cultured podocytes (e) and MCT cells (f). Secretory visfatin protein levels were measured by ELISA. Cells were exposed to a high-glucose
medium (30mM of D-glucose) or angiotensin II (100 nM) for 48 h. The data are shown as the mean±s.e.m. Adipo, 3T3L1 adipocytes;
Ang-II, angiotensin II; HG, high glucose; MCT, MCT cells; MM, 100-bp molecular weight marker; NC, negative control; NG, normal glucose;
Pod, podocytes. *P¼ 0.031 versus NG; ***Po0.001 versus NG ; n¼ 6 in each condition.
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Visfatin expression was markedly upregulated in the diabetic
kidney both in the glomeruli and proximal tubules. In
addition, stimulation with high glucose, but not angiotensin II,
markedly upregulated visfatin synthesis in both glomerular
podocytes and PTCs. Interestingly, visfatin-stimulated glu-
cose uptake in glomerular podocytes and PTCs was mediated
by GLUT-1. Furthermore, administration of exogenous
visfatin induced increased synthesis of pro-fibrotic and pro-
inflammatory molecules, including TGFb1, PAI-1, MCP-1,
and type-I collagen. Together, these results suggest that
endogenous visfatin produced by podocytes and PTCs can
stimulate glucose uptake and is followed by accelerated glucose-
mediated metabolic abnormalities in the diabetic kidney.
Adipose tissue is now believed to be an endocrine organ,
and within this tissue, the visfatin gene in humans is known
to be expressed predominantly in the visceral layer rather
than in the subcutaneous layer.19 Adipocytokines, which are
secreted by adipose tissue, have been studied for their
association with insulin resistance and metabolic syndrome,
including glucose intolerance and hyperlipidemia. Visfatin
binds directly to the IR at a site distinct from insulin, where it
exerts a hypoglycemic effect by reducing glucose release from
hepatocytes and stimulating glucose utilization in peripheral
tissue.20 Recent clinical studies have shown that plasma levels
of visfatin are increased in obese and type-2 diabetic patients,
and are related to insulin resistance.8,21
The results of several studies have begun to elucidate the
role of visfatin as an adipocytokine in obesity, metabolic
syndrome, and cardiovascular disease. Conversely, there is
some doubt as to whether visfatin is an actual adipocyto-
kine.22 Other studies have reported that visfatin is distributed
ubiquitously in all tissues and exists primarily in the cell
nucleus and cytoplasm.23,24 Furthermore, these studies also
showed that visfatin is secreted during adipocyte differentia-
tion and cell lysis in a cell-cycle-dependent manner.23,24
Therefore, the role of visfatin as a secreted protein should be
interpreted with caution. Thus, elucidation of the potential
role for visfatin remains an attractive research target, given its
already-described insulin-mimicking biological and physio-
logical effects.
However, recent studies have also provided evidence that
visfatin has pro-inflammatory properties and that its
expression is increased in inflammatory conditions such as
acute lung injury, sepsis, and rheumatoid arthritis.10,17,25 In
addition, plasma visfatin concentrations have been correlated
with endothelial dysfunction in type-2 diabetic patients and
patients with CKD.15,16 Furthermore, several studies have
failed to identify an association between circulating levels of
visfatin and insulin sensitivity.26–29 Collectively, these results
suggest a new physiological role of visfatin in organ injury.
To the best of our knowledge, this is the first report to
show that visfatin is synthesized in the kidney and that its
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Figure 3 | Effect of visfatin on 2-DOG uptake in experimental cells. (a) 2-DOG uptake in podocytes. (b) 2-DOG uptake in MCT cells.
Experimental cells were treated in the presence or absence of 100 ng/ml of visfatin at the indicated time intervals. In some wells, 10 mM of
cytochalasin-B, an inhibitor of glucose transporters, was pretreated for 30min before visfatin treatment. As positive control, 100 nM of insulin
was used. Radioactivity was normalized for total protein concentration in each condition and 2-DOG uptake was expressed as a % change
compared with controls. The dose-dependent effect of visfatin on 2-DOG uptake in podocytes (c) and MCT cells (d). Because peak glucose
uptake occurred at 20min, cells were treated with different concentrations of visfatin at final concentrations of 1, 10, or 100 ng/ml for
20min, and glucose uptake was measured. The data are shown the mean±s.e.m. CyB, cytochalasin-B. (a): *P¼ 0.041 and ***Po0.001 versus
control; #P¼ 0.032 and ##P¼ 0.007 versus visfatin; (b): *P¼ 0.026 and **P¼ 0.003 and ***Po0.001 versus control; #P¼ 0.041 and ##P¼ 0.003
versus visfatin; (c): **P¼ 0.005 and ***Po0.001 versus control; (d): *P¼ 0.035 and **Po0.006 versus control; n¼ 6 in each condition.
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synthesis is upregulated in the diabetic kidney. In this study,
we used OLETF rats, which are a genetic model of type-2
diabetes mellitus and are characterized by insulin resistance
and obesity.30 These characteristics make this model
appropriate for a type-2 diabetic animal model. The insulin
resistance status of OLETF rats was clearly shown by GTT,
which showed that plasma levels of insulin and HOMA-IR
were significantly increased, and that these changes were
accompanied by lipid abnormalities. Interestingly, plasma
levels of visfatin were significantly increased in type-2
diabetic rats, which is consistent with a report by Chen
et al.,21 which shows that plasma visfatin concentrations are
elevated in type-2 diabetic patients.
In this study, we found that plasma visfatin concentrations
were elevated during the early stages of diabetic nephropathy
and were correlated with body weight, microalbuminuria,
fasting plasma glucose, and HOMA-IR. Although it was not
clear whether the early increase in plasma visfatin levels in
diabetic rats had a causative role in tissue injury as a pro-
inflammatory molecule or whether it was a compensatory
response to decrease insulin resistance, the association with
microalbuminuria was interesting. These results support the
possibility that in addition to obesity and metabolic
syndrome, visfatin may be associated with diabetic nephro-
pathy and/or have a role as an early marker of diabetic
nephropathy through microalbuminuria.
Hyperglycemia in diabetes is associated with increased
glucose uptake into cells, which leads to cellular metabolic
alterations that have long been considered an important
pathophysiological mechanism for diabetic microvascular
complications.31,32 There are many studies suggesting that
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increased glucose uptake by MCs induces the accumulation
of mesangial extracellular matrix protein, which is a
pathological feature of diabetic nephropathy.33,34 Although
there is not sufficient evidence to indicate that increased
glucose uptake in podocytes and PTCs could induce direct
metabolic alterations in these cells, it is generally considered
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that increased glucose uptake is the primary pathological
mechanism for diabetic tissue injury.
In this study, high-glucose stimulation was found to
significantly increase the synthesis of visfatin; however,
angiotensin II, another important mediator of diabetic
nephropathy, did not similarly induce upregulation of
visfatin synthesis. This result is in agreement with a recent
report showing that infusion of exogenous glucose increases
plasma visfatin levels in a healthy population.35 These results
suggest the possibility that a high-glucose condition in a
diabetic environment could continuously stimulate visfatin
synthesis from podocytes and PTCs in vivo.
We also observed that treatment with visfatin rapidly
stimulated 2-DOG uptake in podocytes and PTCs. In
addition, the visfatin-induced increase in 2-DOG uptake
could be abolished by the addition of cytochalasin-B in
visfatin-treated cells, suggesting that 2-DOG uptake occurred
primarily through facilitative glucose transporters. However,
cytochalasin-B is not a specific inhibitor of glucose
transporters but an endocytosis inhibitor that blocks several
cellular functions. It may be possible that inhibition of
endocytosis mediated by cytochalasin-B may affect cellular
function independent of effects of decreased glucose uptake
into cells. In line with this observation, we found that
expression of GLUT-1, which is a constitutional glucose
transporter and is present at the plasma membrane of most
cells,36,37 was significantly increased after visfatin treatment.
In addition, we observed that treatment with visfatin resulted
in the translocation of GLUT-1 in both podocytes and PTCs.
This translocation was observed after 10 min of visfatin
stimulation and peaked at 20 min of stimulation. These
results were in agreement with the 2-DOG uptake results,
which showed maximal uptake after 20 min of visfatin
stimulation. Western blot analysis using the membrane
fraction of cells clearly showed translocation of GLUT-1
after visfatin stimulation.
We also studied whether the downstream signaling
molecules induced by glucose uptake in cells were activated
in response to visfatin treatment. We observed that visfatin
treatment induced the tyrosine phosphorylation of the IR
and IRS-1, and binding of p85 to IRS-1 molecule in both
podocytes and PTCs. Interestingly, we found that protein
kinase-B, which is an important downstream target of
phosphoinositide-3-kinase and has an important role in
glucose metabolism, was activated by visfatin treatment. We
also observed that visfatin was able to activate Erk-1/2 and
p38 MAPK, both of which are important regulators of cell
proliferation and extracellular matrix synthesis. This result
suggested that visfatin treatment activated IR signaling
pathway and induced glucose uptake, which was followed
by activation of Akt, Erk-1/2, and p38 MAPK, all of which are
downstream signaling molecules of cellular glucose influx.
Another important finding in this study was that
exogenous visfatin treatment increased the synthesis of pro-
fibrotic and pro-inflammatory molecules such as TGFb1,
PAI-1, MCP-1, and type-I collagen. The visfatin-induced
increase in these molecules could be abrogated by cytocha-
lasin-B treatment, suggesting that visfatin-induced TGFb1,
PAI-1, MCP-1, and type-I collagen synthesis was mediated by
cellular glucose uptake. On the basis of these observations, we
hypothesized that increased visfatin production under high-
glucose conditions induced an increase in endogenous
visfatin synthesis from renal cells, and consequently, visfatin
could stimulate glucose uptake to accelerate metabolic
alterations, including overproduction of pro-fibrotic mole-
cules. The interaction between visfatin and GLUT-1 shown in
this study may elucidate a new physiological role of visfatin
in the pathogenetic mechanism of diabetic nephropathy.
These results are in agreement with recent reports that
circulating levels of visfatin are associated with endothelial
dysfunction in patients with CKD and that visfatin itself
activates various pro-inflammatory cytokines in cultured
synovial fibroblasts.15–17
In conclusion, the results of this study suggest a new
physiological role of visfatin in diabetic nephropathy. Visfatin
synthesis was markedly increased in diabetic glomeruli and
tubules in type-2 diabetic rats. Plasma visfatin concentrations
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experimental cells. Effect of MAPK inhibitors on glucose uptake
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were significantly elevated in the early stages of diabetic
nephropathy. On the basis of these results, we hypothesize
that increased visfatin synthesis from renal cells under high-
glucose conditions possibly contributes to increased glucose
influx into cells through GLUT1, thereby accelerating
diabetic nephropathy through aggravation of metabolic
alterations. Thus, visfatin may have an important role in
the pathogenesis of diabetic nephropathy. More in vivo
studies are necessary to define the role of visfatin in the
pathogenesis of diabetic nephropathy.
METHODS
Animal studies
OLETF rats were supplied by the Tokushima Research Institute
(Otsuka Pharmaceutical Co., Tokyo, Japan) and were used as a type-2
diabetic model. Age-matched male LETO rats served as the genetic
control for OLETF rats. Rats at 16 weeks of age had free access to rat
food and tap water, and were caged individually under a controlled
temperature (23±2 1C) and humidity (55±5%) environment with
an artificial light cycle. At the end of the study period, systolic blood
pressure was measured by tail-cuff plethysmography (LE 5001-
Pressure Meter; Letica SA, Barcelona, Spain). Plasma glucose levels
were measured by a glucose oxidase-based method and creatinine
levels were determined by a modified Jaffe method. Plasma insulin
levels and plasma adiponectin levels were measured using an ELISA
kit (Linco Research, St Charles, MO, USA). The HOMA-IR was
calculated using the following formula: fasting glucose (mmol/
l) fasting insulin (mU/l)/22.5. Plasma triglyceride and cholesterol
analyses were performed using a GPO-Trinder kit (Sigma, St Louis,
MO, USA). A GTT was performed to assess the insulin resistance
status of each group. GTTs were performed after an 8-h fasting
period and blood samples were collected through the tail vein. Rats
received 2 g dextrose/kg body weight by intraperitoneal injection for
GTT, and blood sampling was performed to measure blood glucose
levels at 0, 30, 60, 90, and 120 min after glucose loading. To
determine urinary albumin excretion, individual rats were caged in
metabolic cages and 24-h urine samples were collected at 20 weeks
of age and at the end of the study. Urinary albumin concentrations
were determined by competitive ELISA (Shibayagi, Shibukawa,
Japan) and corrected for urinary creatinine concentration. Plasma
visfatin concentrations were measured with a visfatin enzyme
immunoassay kit (Phoenix Pharmaceuticals, Burlingame, CA, USA)
at 20 weeks of age and at the end of the study. Rats were killed under
anesthesia by intraperitoneal injection of sodium pentobarbital
(50 mg/kg). All experiments were conducted in accordance with the
Korea University Guide for Laboratory Animals.
Analysis of gene expression by real-time quantitative PCR in
renal tissues and cells
Total RNA was extracted from renal cortical tissues or experimental
cells using Trizol reagent and further purified using an RNeasy Mini
kit (Qiagen, Valencia, CA, USA). Primers were designed from
respective gene sequences using the Primer 3 software, and
templates’ secondary structures were examined and excluded using
the mfold software. Table 3 shows the nucleotide sequences of all of
the primers used in this study. Quantitative gene expression was
performed with a LightCycler 1.5 system (Roche Diagnostics
Corporation, Indianapolis, IN, USA) using SYBR Green technology.
Real-time reverse transcription-PCR was performed for 10 min at
50 1C and 5 min at 95 1C. Subsequently, 23–30 cycles were applied,
which consisted of denaturation for 10 s at 95 1C and annealing with
extension for 30 s at 60 1C. At the end of the 30 cycles, samples were
heated to 95 1C to verify that a single PCR product was obtained
during amplification. The ratio of each gene and b-actin level
(relative gene expression number) was calculated by subtracting the
threshold cycle number (Ct) of the target gene from that of b-actin
and raising 2 to the power of this difference.
Histological examination and immunohistochemical
staining for visfatin
Kidney tissues embedded in paraffin were cut into 4-mm-thick slices
and stained with periodic acid–Schiff stain. A semi-quantitative
score (SI) was used to evaluate the degree of glomerulosclerosis on
periodic acid–Schiff-stained sections according to the method
described by Ma et al.38 The severity of sclerosis for each glomerulus
was graded from 0 to 4þ as follows: 0, no lesion; 1þ , sclerosis of
o25% of the glomerulus; 2þ , 3þ , and 4þ , sclerosis of 25–50%,
450–75%, and 475% of the glomerulus, respectively. For
immunohistochemical staining, renal tissues were sliced into 4-mm
sections and after removal of paraffin and dehydration in xylene
followed by graded alcohol concentrations, slides were transferred to
a 10-mmol/l citrate buffer solution at pH 6.0. The sections were then
heated at 80 1C for 10 min to retrieve antigens for visfatin staining,
and after washing the slides in water, 3.0% H2O2 in methanol was
applied for 20 min to block endogenous peroxidase activity, and the
slides were then incubated at room temperature for 20 min with
normal goat serum to prevent nonspecific detection. Next, slides
were incubated for 1 h with primary antibody against rabbit
polyclonal anti-visfatin (1:500; Phoenix Pharmaceuticals, Burlin-
game, CA, USA). The slides were incubated in secondary antibody
for 30 min. For coloration, slides were incubated at room
temperature with a mixture of 0.05% 3,30-diaminobenzidine
containing 0.01% H2O2 and counterstained with Mayer’s hematox-
ylin. Negative control sections were stained under identical
conditions except that the buffer solution was used in place of the
primary antibody (Supplementary Figure S4). To evaluate the results
of immunohistochemical staining, glomerular and tubulointerstitial
fields were graded semi-quantitatively by means of grid fields that
measured 0.245 mm2. Briefly, each score was assigned such that it
reflected both changes in the extent and intensity of staining. All
fields were graded according to a four-point scale, with grade-0
representing absent or o25% of the area positive staining; grade-1,
25–50% of the area positive staining; grade-2, 50–75% of the area
positive staining; grade-3, 475% of the area positive staining. More
than 50 and 60 glomeruli, and 10 randomly selected tubulointer-
stitial fields were evaluated under high-power fields ( 400) and
average scores were calculated by a pathologist in a masked manner.
Podocytes and PTC culture
A thermosensitive SV 40-transfected immortalized mouse podocyte
cell line that was obtained as a generous gift from Peter Mundel at
the Albert Einstein College of Medicine (NY, USA) was used for this
study. Cultivation of mouse podocytes, which were conditionally
immortalized with a temperature-sensitive variant of the SV40 large
T-antigen (tsA58) and whose activity could be increased by
stimulation with g-interferon, was performed as described pre-
viously.39 Studies were performed using podocytes at 24–28
passages. MCT cells are a cultured line of PTCs harvested originally
from the renal cortex of SJL mice and functionally characterized by
Haverty et al. (a generous gift from Eric G. Neilson, Vanderbilt
University, Nashville, TN, USA).40 The cells were grown in
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Dulbecco’s modified eagles medium supplemented with 10% fetal
calf serum as described previously.40 To evaluate the effect of high
glucose and angiotensin II on visfatin synthesis, sub-confluent
podocytes and PTCs were serum-starved for 24 h, and the medium
was then replaced with media containing 30 mM D-glucose or 100 nM
angiotensin II. For the group stimulated with visfatin, different
concentrations of visfatin were added to the culture media at final
concentrations of 1, 10, and 100 ng/ml. In some wells, cells were
pretreated for 30 min with 10 mM of cytochalasin-B, an inhibitor of
glucose transporters, before visfatin treatment. All experimental
groups were cultured in triplicate and harvested at 48 h for
extraction of total RNA and protein.
Measurement of glucose uptake in podocytes and PTCs
Cells were starved in serum-free medium for 16 h and then washed
three times with phosphate-buffered saline buffer. Cells were then
incubated in 1 ml of Krebs-Ringer phosphate Hepes buffer (136 mM
NaCl, 4.7 mM KCl, 1.2 mM CaCl2, 2.5 mM Na2HPO4, 10 mM Hepes,
and 0.1% (w/v) bovine serum albumin, pH 7.4) for 30 min at 37 1C.
The cells were then treated with or without 100 ng/ml of visfatin or
100 nM of insulin and incubated for 15 min at 37 1C. The cells were
next incubated with 1 mCi of 2-deoxy-[1–3H]-D-glucose and
incubated at the indicated time points, which ranged from 10 to
30 min. To exclude non-carrier-mediated glucose uptake, control
wells were pretreated with 10 mM cytochalasin-B for 30 min. In some
wells, 10 mM of cytochalasin-B, an inhibitor of glucose transporters,
was pretreated for 30 min before initiating visfatin treatment. At
the indicated time points, media was collected, cells washed
three times with phosphate-buffered saline buffer, and lysed
in 0.1 N NaOH for 1 h at room temperature (RT). Total radio-
activity from media (Rm) and total cell-associated radioactivity from
lysates (Rc) were counted using a liquid scintillation counter. True
glucose uptake was calculated as follows: glucose uptake¼ [R(c)/
(R(m)þR(c))]sample[R(c)/(R(m)þR(c))]cytochalasin-B. Radioactivity
was normalized for total protein as quantified by the Bradford
method. Next, the dose dependency of visfatin in glucose uptake was
determined. As peak glucose uptake occurred at 20 min, cells were
treated with different concentrations of visfatin at final concentra-
tions of 1, 10, or 100 ng/ml for 20 min, and glucose uptake was
measured as described above. Next, we determined whether
pharmacological inhibition of MAPK inhibits visfatin-induced
glucose uptake. All MAPK inhibitors were purchased from
Calbiochem (EMD chemicals, Darmstadt, Germany). Experimental
cells were pretreated with various MAPK inhibitors, including
LY294002 (PI3K inhibitor, 1 mM), Akt inhibitor (10mM), U-0126
(Erk inhibitor, 40 mM), and SB 203580 (p38 MAPK inhibitor, 10 mM)
for 30 min before being incubated with visfatin (100 ng/ml) for
30 min.
Determination of insulin signal transduction in podocytes
and PTCs
To determine whether the biological effect of visfatin is mediated
through the insulin signaling pathway, we checked the tyrosine
phosphorylation of the IR and IRS-1 as well as binding of PI3K p85
to IRS-1 in the presence or absence of 100 ng/ml of visfatin in
cultured cells. For measurement of tyrosine phosphorylation of the
IR and IRS-1, cellular protein extract was analyzed by immunopre-
cipitation with an antibody to the IR (1:50; Cell Signaling
Technology, MA, USA) and IRS-1 (1:50; Cell Signaling Technology,
MA, USA), and detected by immunoblotting using an antibody to
phosphotyrosine (1:50; Cell Signaling Technology, MA, USA). To
determine the binding of p85 to IRS-1, immunoprecipitation was
also performed using an antibody to IRS-1 and detected by
immunoblotting using an antibody to PI3K p85 (10 mg/ml per
100 mg of cellular protein; Abcam, Cambridge, USA).
Protein extraction, fractionation, and western blot analysis
For studying total cellular lysates, cells were lysed in lysis buffer
(150 mM NaCl, 50 mM Tris–HCl, pH 8.0, 1% Triton X-100, 1 mM
phenylmethylsulfonylfluoride) and the lysate was boiled for 3 min.
For microsomal preparations of cells, whole-cell extracts were
prepared by incubating the cells in lysis buffer (20 mM Tris–HCl,
100 mM NaCl, 5 mM MgCl2, 1% NP-40, 0.5% sodium deoxychlolate,
10 mM b-glycerophosphate, 0.1 mM orthovanadate, and protease
inhibitors) for 30 min. Cytosol and membrane fractions were
prepared using the Qproteom Cell Compartment kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s instructions.
Protein concentrations were measured by BCA protein assay (Pierce,
Rockford, IL, USA). Fifty micrograms of each protein sample was
loaded for electrophoresis on a 10% SDS–polyacrylamide gel (Tefco,
Table 3 | Primer sequences for real-time quantitative PCR
Target gene Primer sequence (50 to 30) Amplicon length (bp) Number of PCR cycles
Mouse visfatin, forward TGCCGTGAAAAGAAGACAGA 143 24
Mouse visfatin, reverse ACTTCTTTGGCCTCCTGGAT
Mouse GLUT-1, forward TGCAGTTCGGCTATA ACACC 122 30
Mouse GLUT-1, reverse ACACCTCCCCCACATACATG
Mouse MCP-1, forward CTGGATCGGAACCAAATGAG 95 25
Mouse MCP-1, reverse CGGGTCAACTTCACATTCAA
Mouse PAI-1, forward TCCTCATCCTGCCTAAGTTCTC 365 24
Mouse PAI-1, reverse GTGCCGCTCTCGTTTACCTC
Mouse TGFb1, forward ATACAGGGCTTTCGATCCAGG 96 28
Mouse TGFb1, reverse GTCCAGGCTCCAAATATAGG
Mouse PCa1(I), forward TGGTCCCTCTGGAAATGCTGGACC 107 27
Mouse PCa1(I), reverse CAGGAGAACCAGGAGAACCAGG
Mouse b-actin, forward GGACTCCTATGTGGGTGACG 118 23
Mouse b-actin, reverse CTTCTCCATGTCGTCCCAGT
Abbreviations: GLUT-1, glucose transporter-1; MCP-1, monocyte chemoattractant peptide-1; PAI-1, plasminogen activator inhibitor-1; PCa1(I), pro-collagen-a1 in type-I
collagen; TGFb1, transforming growth factor-b1.
In this experiment, each sample was run in triplicate and the corresponding non-reverse transcribed mRNA sample was used as negative control. The mRNA level of each
sample was normalized to that of b-actin mRNA.
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Tokyo, Japan) under denaturing conditions. The proteins were
transferred onto a polyvinylidene difluoride membrane (Immobi-
lon-P; Millipore, Bedford, MA, USA) for 120 min at 250 mA. After
the membrane was blocked by incubating with a blocking solution
(Tris-buffered saline containing 150 mM NaCl, 50 mM Tris, 0.05%
Tween-20 and 5% non-fat milk, pH 7.5) for 1 h at RT, the
membrane was hybridized in blocking buffer overnight at 4 1C with
either rabbit polyclonal anti-GLUT-1 antibody (1:500; Abcam,
Cambridge, USA); rabbit polyclonal anti-MCP-1 antibody (1:200;
Santa Cruz Biotechnology, Santa Cruz, CA, USA); rabbit polyclonal
anti-PAI-1 antibody (1:500; Santa Cruz Biotechnology, Santa Cruz,
CA, USA); rabbit monoclonal Akt and phospho-specific Akt
antibody (1:1000; Cell Signaling Technology, MA, USA); rabbit
monoclonal antibody to p38 MAPK, phospho-specific p38 MAPK
(1:1000; Cell Signaling Technology, MA, USA); or rabbit mono-
clonal Erk-1/2, phospho-specific Erk-1/2 antibody (1:2000; Cell
Signaling Technology, MA, USA). To confirm equal loading and
proper microsomal fractionation of protein, goat polyclonal anti-
AIF (apoptosis-inducing factor) antibody (1:200; US Biological,
Swampscott, MA, USA) was applied to the membrane in blocking
buffer overnight at 4 1C. The filter was then washed four times with
TBST and incubated with horseradish peroxidase-conjugated
secondary antibody diluted 1:1000 for 60 min at RT. Specific signals
were detected by the enhanced chemiluminiscence method (Amer-
sham, Buckinghamshire, UK).
Measurement of secreted visfatin, MCP-1, PAI-1, and collagen
in cultured supernatants
Secreted visfatin and total soluble collagen was measured in culture
supernatants by using the visfatin enzyme immunoassay kit
(Phoenix Pharmaceuticals, Burlingame, CA, USA) and the Sircol
soluble collagen assay kit (Biocolor, Belfast, Ireland) according to the
manufacturer’s instructions. For visfatin measurement, 50 ml of
sample was incubated at RT for 2 h with 25 ml of primary antiserum
and 25 ml of biotinylated peptide in a secondary-antibody-coated
plate. The plates were then washed five times with 300 ml of assay
buffer. Next, 100ml of streptavidin–horseradish peroxidase solution
was added and the plates were incubated at RT for 1 h. After washing
six times, 100 ml of substrate solution was incubated at RT for 1 h
and the reaction was terminated by addition of 2 N HCl. Absorbance
was then measured at 450 nm using an ELISA reader. To measure
collagen, 1 ml of Sirius red reagent was added to 100ml of test
samples and mixed for 60 min at RT using a mechanical shaker. The
collagen–dye complex was precipitated by centrifugation at 14,000 g
for 10 min. To release bound dye, 1 ml of alkali reagent (0.5 M
NaOH) was added to the precipitate and then absorbance was
measured at 540 nm using an ELISA reader. MCP-1 and PAI-1 levels
were measured by quantitative sandwich ELISA using a commercial
kit (MCP-1, Biosource, Camarillo, CA, USA; PAI-1, American
Diagnostica, Stamford, CT, USA), according to the manufacturer’s
instructions. The supernatant levels of visfatin, MCP-1, PAI-1, and
collagen were expressed relative to the total protein concentration
under each condition.
Statistical analysis
A non-parametric analysis was used as most of the variables,
especially in vivo data except kidney/body weight, fasting plasma
glucose, and systolic blood pressure, were not normally distributed
even after logarithmic transformation. Results are expressed as the
mean±s.e.m. A Kruskall–Wallis test was used for comparison of
more than two groups followed by a Mann–Whitney U-test for
comparison, all of which was performed using a microcomputer-
assisted program with SPSS for Windows 10.0 (SPSS, Chicago, IL,
USA). Correlations between plasma visfatin levels and biochemical
parameters were examined using Spearman’s rank correlation test.
Values of Po0.05 were considered statistically significant.
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